Do analysts prefer BBLG or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BBLG or MBAI?

Bone Biologics is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$2.27 N/A Check-Cap N/A N/A $4.14M -$2.77 N/A

Is BBLG or MBAI more profitable?

Check-Cap's return on equity of 0.00% beat Bone Biologics' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% Check-Cap N/A N/A N/A

Do analysts rate BBLG or ALUR?

Allurion Technologies has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Allurion Technologies is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SINT or BBLG?

Sintx Technologies presently has a consensus price target of $9.33, suggesting a potential upside of 396.19%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BBLG or HSCS?

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 205.93%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, BBLG or HSCS?

Bone Biologics is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$2.27 N/A HeartSciences N/A N/A -$8.77M -$4.94 N/A

Is BBLG or HSCS more profitable?

Bone Biologics' return on equity of -50.47% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% HeartSciences N/A -333.50% -140.18%

Do analysts recommend BBLG or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 378.93%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, BBLG or NDRA?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$2.27 N/A ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A

Is BBLG or NDRA more profitable?

Bone Biologics' return on equity of -50.47% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -50.47% -47.40% ENDRA Life Sciences N/A -433.64% -204.58%

Bone Biologics (BBLG) Competitors

$1.33 -0.04 (-2.63%)

As of 11:17 AM Eastern

Compare

BBLG vs. MBAI, ALUR, SINT, HSCS, and NDRA

Should you buy Bone Biologics stock or one of its competitors? MarketBeat compares Bone Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bone Biologics include Check-Cap (MBAI), Allurion Technologies (ALUR), Sintx Technologies (SINT), HeartSciences (HSCS), and ENDRA Life Sciences (NDRA). These companies are all part of the "medical equipment" industry.

How does Bone Biologics compare to Check-Cap?

Bone Biologics (NASDAQ:BBLG) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Bone Biologics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, Check-Cap had 2 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for Check-Cap and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.87 beat Check-Cap's score of 0.36 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Very Positive
Check-Cap	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bone Biologics is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

Check-Cap's return on equity of 0.00% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Check-Cap	N/A	N/A	N/A

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 7.5% of Bone Biologics shares are owned by insiders. Comparatively, 0.5% of Check-Cap shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bone Biologics and Check-Cap tied by winning 5 of the 10 factors compared between the two stocks.

How does Bone Biologics compare to Allurion Technologies?

Bone Biologics (NASDAQ:BBLG) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 7.5% of Bone Biologics shares are owned by insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bone Biologics has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
Allurion Technologies	-199.96%	N/A	-77.13%

Allurion Technologies has a consensus target price of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Allurion Technologies is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics has higher earnings, but lower revenue than Allurion Technologies. Bone Biologics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A

In the previous week, Allurion Technologies had 1 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for Allurion Technologies and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.87 beat Allurion Technologies' score of -0.36 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Very Positive
Allurion Technologies	Neutral

Bone Biologics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

Summary

Allurion Technologies beats Bone Biologics on 9 of the 15 factors compared between the two stocks.

How does Bone Biologics compare to Sintx Technologies?

Sintx Technologies (NASDAQ:SINT) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Bone Biologics has lower revenue, but higher earnings than Sintx Technologies. Bone Biologics is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	7.97	-$10.36M	-$5.07	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

Bone Biologics has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,058.60%. Bone Biologics' return on equity of -50.47% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
Bone Biologics	N/A	-50.47%	-47.40%

Sintx Technologies has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Sintx Technologies presently has a consensus price target of $9.33, suggesting a potential upside of 396.19%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by insiders. Comparatively, 7.5% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Sintx Technologies had 1 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for Sintx Technologies and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.87 beat Sintx Technologies' score of 1.43 indicating that Bone Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sintx Technologies	Positive
Bone Biologics	Very Positive

Summary

Bone Biologics beats Sintx Technologies on 9 of the 15 factors compared between the two stocks.

How does Bone Biologics compare to HeartSciences?

Bone Biologics (NASDAQ:BBLG) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 205.93%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics' return on equity of -50.47% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
HeartSciences	N/A	-333.50%	-140.18%

Bone Biologics is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

Bone Biologics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

In the previous week, HeartSciences had 1 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.87 beat HeartSciences' score of 0.70 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Very Positive
HeartSciences	Positive

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 7.5% of Bone Biologics shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Bone Biologics beats HeartSciences on 7 of the 13 factors compared between the two stocks.

How does Bone Biologics compare to ENDRA Life Sciences?

Bone Biologics (NASDAQ:BBLG) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 378.93%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 7.5% of Bone Biologics shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bone Biologics' return on equity of -50.47% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

In the previous week, ENDRA Life Sciences had 9 more articles in the media than Bone Biologics. MarketBeat recorded 10 mentions for ENDRA Life Sciences and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.87 beat ENDRA Life Sciences' score of 0.58 indicating that Bone Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
Bone Biologics	Very Positive
ENDRA Life Sciences	Positive

Summary

Bone Biologics beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBLG vs. The Competition

Export

Metric	Bone Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.40M	$3.66B	$6.81B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.59	21.44	27.52	25.33
Price / Sales	N/A	339.00	539.41	102.00
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.44	8.75	10.94	6.61
Net Income	-$3.11M	$23.87M	$3.57B	$336.72M
7 Day Performance	-1.19%	3.51%	2.69%	2.63%
1 Month Performance	4.22%	3.56%	1.84%	0.24%
1 Year Performance	-63.75%	67.21%	36.35%	29.97%

Bone Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBLG Bone Biologics	1.174 of 5 stars	$1.33 -2.6%	N/A	-66.0%	$2.40M	N/A	N/A	2	Positive News Gap Down
MBAI Check-Cap	0.2468 of 5 stars	$1.11 -14.0%	N/A	N/A	$9.40M	N/A	N/A	80	Short Interest Increase
ALUR Allurion Technologies	1.4313 of 5 stars	$0.58 flat	$45.00 +7,658.6%	-98.4%	$8.70M	$17.21M	N/A	501	News Coverage
SINT Sintx Technologies	3.9681 of 5 stars	$1.86 -5.1%	$9.33 +401.8%	-41.9%	$8.47M	$1.02M	N/A	40	Short Interest Decrease
HSCS HeartSciences	2.2353 of 5 stars	$2.99 +13.7%	$8.00 +167.6%	-33.6%	$8.38M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBLG) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bone Biologics (BBLG) Competitors

BBLG vs. MBAI, ALUR, SINT, HSCS, and NDRA

How does Bone Biologics compare to Check-Cap?

Summary

How does Bone Biologics compare to Allurion Technologies?

Summary

How does Bone Biologics compare to Sintx Technologies?

Summary

How does Bone Biologics compare to HeartSciences?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bone Biologics (BBLG) Competitors

BBLG vs. MBAI, ALUR, SINT, HSCS, and NDRA

How does Bone Biologics compare to Check-Cap?

Which has more volatility and risk, BBLG or MBAI?

Does the media refer more to BBLG or MBAI?

Do analysts prefer BBLG or MBAI?

Which has better valuation and earnings, BBLG or MBAI?

Is BBLG or MBAI more profitable?

Do institutionals & insiders hold more shares of BBLG or MBAI?

Summary

How does Bone Biologics compare to Allurion Technologies?

Do institutionals and insiders believe in BBLG or ALUR?

Is BBLG or ALUR more profitable?

Do analysts rate BBLG or ALUR?

Which has better earnings and valuation, BBLG or ALUR?

Does the media favor BBLG or ALUR?

Which has more volatility & risk, BBLG or ALUR?

Summary

How does Bone Biologics compare to Sintx Technologies?

Which has stronger earnings and valuation, SINT or BBLG?

Is SINT or BBLG more profitable?

Which has more volatility and risk, SINT or BBLG?

Do analysts rate SINT or BBLG?

Do institutionals & insiders hold more shares of SINT or BBLG?

Does the media prefer SINT or BBLG?

Summary

How does Bone Biologics compare to HeartSciences?

Do analysts recommend BBLG or HSCS?

Is BBLG or HSCS more profitable?

Which has higher earnings & valuation, BBLG or HSCS?

Which has more risk and volatility, BBLG or HSCS?

Does the media favor BBLG or HSCS?

Do institutionals & insiders hold more shares of BBLG or HSCS?

Summary

How does Bone Biologics compare to ENDRA Life Sciences?

Which has preferable valuation & earnings, BBLG or NDRA?

Do analysts recommend BBLG or NDRA?

Which has more volatility and risk, BBLG or NDRA?

Do institutionals and insiders hold more shares of BBLG or NDRA?

Is BBLG or NDRA more profitable?

Does the media favor BBLG or NDRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools